DexCom (NASDAQ:DXCM) 株価情報

DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

Equities

News

Markets

ASTS

DXCM

TSLA

先週木曜日、主要な米国株指数は反発を推移した。ダウ平均は0.2%高の3万9935ドル、一方でS＆P500は0.5%安の5392ドルで取引を終了した。ナスダックは0.9%安の17182ドルで終了した。

米国株式市場　テスラが市場を牽引　NBA契約でディズニーも上昇

DexCom Inc

On Thursday, Dexcom, Inc.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) fourth-quarter&nbsp;revenue rose 8% year-over-year to&nbsp;$1.114 billion,&nbsp;beating the analyst consensus <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">estimate of&nbsp;$1.104 billion</a>.
U.S. revenue rose by 4%, while international revenue rose by 17% on a reported basis and <a target="_blank" href="https://www.benzinga.com/25/02/43728537/dexcom-tops-sales-forecasts-as-international-growth-soars-19" rel="noreferrer noopener">19% on an organic basis</a>.
Outlook: Dexcom reaffirmed its FY25 guidance for revenue of $4.60 billion (vs. cons. of $4.61 billion), adjusted gross profit margin of around 64%–65%, and<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> adjusted operating margin of 21%</a>.
In December, Abbott Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reached an agreement with DexCom to settle all outstanding patent disputes related to continuous glucose monitoring products.
The agreement <a target="_blank" href="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom" rel="noreferrer noopener">will</a> dismiss all pending cases in courts and patent offices worldwide. It also includes a provision that the parties will not litigate patent, trade dress, and design rights disputes with each other for the next 10 years. No financial payments are associated with the settlement from Abbott or Dexcom.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42274583/morgan-stanley-maintains-positive-medtech-outlook-despite-setbacks-in-2024-upgrades-intuitive-surgical-and-stryker-downgrades-nevro-and-glaukos" rel="noreferrer noopener">Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos</a>
Analyst Reactions: William Blair writes that DME's market share remained steady in Q4, and productivity has improved as planned, following a 40% commercial team expansion last year.
The analyst says the management expects further gains in productivity and another record year for new patient additions in 2025.&nbsp;&nbsp;
While the benefits of these improvements will take several quarters to materialize, especially as 2024 execution challenges fade in the second half, analyst Margaret Kaczor Andrew sees multiple growth drivers that could boost performance in 2025 and sustain revenue and earnings growth in the long term.
Andrew said that DexCom's challenges in 2024 may be temporary. She notes that DexCom is positioned for long-term growth, supported by its expanding product lineup, including G7, Dexcom One, and Stelo, and opportunities to reach new patient groups.
However, the analyst points out that DexCom's growth depends on adding new patients, particularly those with early-stage diabetes, with limited clinical data and reimbursement support.
Competition from major players like Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and Abbott Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) could also impact DexCom's expansion by capturing a share of new or existing patients in the continuous glucose monitoring market.
Morgan Stanley analyst Patrick Wood maintains DexCom with an Equal-Weight rating and raises the price <a target="_blank" href="https://www.benzinga.com/quote/DXCM/analyst-ratings" rel="noreferrer noopener">target from $75 to $82</a>.
Canaccord Genuity analyst William Plovanic maintains DexCom with a Buy and raises the price target from $99 to $103.
Price Action: DXCM stock is up 6.22% at $89.32 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43737281/pfizers-talzennaxtandi-combo-improves-survival-outcomes-in-metastatic-castration-resistant-prostate-cancer" target="_blank" rel="noreferrer noopener">Pfizer's Talzenna/Xtandi Combo Improves Survival Outcomes In Metastatic Castration-Resistant Prostate Cancer</a></li>
</ul>

Analyst Color

Earnings

Large Cap

Guidance

Health Care

Price Target

Analyst Ratings

Movers

Trading Ideas

General

Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom

Financial giants have made a conspicuous bearish move on DexCom. Our analysis of options history for DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) revealed 12 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $399,800, and 8 were calls, valued at $305,770.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $120.0 for DexCom over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for DexCom's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DexCom's whale trades within a strike price range from $60.0 to $120.0 in the last 30 days. 
<h3>DexCom Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739558724_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.3</td>
<td>$4.7</td>
<td>$5.1</td>
<td>$70.00</td>
<td>$145.3K</td>
<td>1.2K</td>
<td align="right">500</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$5.5</td>
<td>$5.3</td>
<td>$5.3</td>
<td>$70.00</td>
<td>$113.4K</td>
<td>1.2K</td>
<td align="right">214</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.7</td>
<td>$6.6</td>
<td>$6.6</td>
<td>$75.00</td>
<td>$109.5K</td>
<td>592</td>
<td align="right">239</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$14.0</td>
<td>$12.1</td>
<td>$14.0</td>
<td>$75.00</td>
<td>$70.0K</td>
<td>50</td>
<td align="right">50</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.45</td>
<td>$1.35</td>
<td>$1.35</td>
<td>$90.00</td>
<td>$47.2K</td>
<td>1.7K</td>
<td align="right">597</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Having examined the options trading patterns of DexCom, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of DexCom</h3>
<ul>
<li>With a trading volume of 4,506,895, the price of DXCM is up by 6.21%, reaching $89.31.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 69 days from now.</li>
</ul>
<h3>Expert Opinions on DexCom</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $101.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on DexCom, maintaining a target price of $82. 
&#x2A; An analyst from Baird upgraded its action to Outperform with a price target of $104. 
&#x2A; In a positive move, an analyst from Redburn Atlantic has upgraded their rating to Buy and adjusted the price target to $115. 
&#x2A; An analyst from Canaccord Genuity persists with their Buy rating on DexCom, maintaining a target price of $103. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for DexCom, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

DexCom Unusual Options Activity

Stocks are headed for weekly gains, with the Dow Jones dipping slightly and the S&amp;P 500 and Nasdaq trading just above the flatline Friday. Traders are digesting weaker-than-expected retail sales and the potential for peace talks<a href="https://www.benzinga.com/news/global/25/02/43732115/explosion-rocks-chernobyl-nuclear-site-as-zelenskyy-signals-readiness-for-peace-talks"> between Russia and Ukraine.&nbsp;</a>
Retail sales in the U.S. fell 0.9% month-over-month in January, significantly worse than the anticipated 0.1% drop. However, markets are largely shrugging off the weaker-than-expected retail sales figures which were likely affected by January's cold weather and California wildfires, as well as the upward revision of December results.
Geopolitical tensions eased slightly after Ukrainian President Volodymyr Zelenskyy<a href="https://www.benzinga.com/news/global/25/02/43732115/explosion-rocks-chernobyl-nuclear-site-as-zelenskyy-signals-readiness-for-peace-talks"> told reporters</a> at the Munich Security Conference on Friday that he is willing to participate in Trump&#8217;s peace initiative and eventual talks with Russia.
The price of Crude Oil slid another 0.52% Friday and is down 9.9% over the past month as the market reacted to President Donald Trump&#8216;s plans to impose reciprocal tariffs on trade partners and news of potential peace talks to end the war in Ukraine.
The yield on the 10-year U.S. Treasury note fell to below the 4.5% threshold on Friday, extending its pullback after January's retail sales data may have indicated some weakness in the U.S. consumer. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) rose 0.7%. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose above the $98,000 level on a midday rally Friday and XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) climbed more than 7%. 
<h2 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100 </td>
<td>19,988.34</td>
<td>0.20%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,116.90</td>
<td>0.03%</td>
</tr>
<tr>
<td>Dow Jones </td>
<td>44,602.67</td>
<td>-0.24%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,278.93</td>
<td>-0.14%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched up 0.3% to $609.92</li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 0.23% at $446.24</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.27% to $537.34.&nbsp;</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.14% to $225.82.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) dipped 0.14% to $226.78</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) rose 0.72% to $90.36.&nbsp;</li>
</ul>
<h2 class="wp-block-heading">Friday's Stock Movers:&nbsp;</h2>
Shares of Serve Robotics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) and SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) tanked after NVIDIA Corp.'s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) latest 13F filing revealed it had dissolved its stakes in both companies.&nbsp;
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>DraftKings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>)&nbsp;</li>
<li>American Axle &amp; Manufacturing Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>)&nbsp;</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>)&nbsp;</li>
<li>JFrog, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FROG#NASDAQ">FROG</a>)&nbsp;</li>
<li>Wynn Resorts Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>)&nbsp;</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>)&nbsp;</li>
<li>Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>)</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)&nbsp;</li>
<li>Procore Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>)&nbsp;</li>
<li>Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>)&nbsp;</li>
<li>Udemy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>)&nbsp;</li>
<li>Nu Skin Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUS#NYSE">NUS</a>)&nbsp;</li>
<li>Bio-Rad Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>)&nbsp;</li>
</ul>
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a></li>
</ul>
Image: Shutterstock

$BTC

$XRP

COIN

SPDR Dow Jones Industrial Average ETF Trust

DKNG

FROG

MRNA

NVDA

PANW

PCOR

ROKU

SERV

SOUN

iShares Trust Barclays 20+ Year Treasury Bond Fund

UDMY

WYNN

Select Sector SPDR-Consumer Discretionary

Stocks Head For Weekly Gains, US Treasury Yields Fall Below 4.5%: What's Driving Markets Friday?

WIIM

DexCom shares are trading higher after Morgan Stanley and Canaccord Genuity raised their respective price targets on the stock.

DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported weaker-than-expected earnings for its <a href="https://www.benzinga.com/quote/DXCM/earnings">fourth quarter on Thursday</a>.
The company posted quarterly earnings of 45 cents per share which missed the analyst consensus estimate of 50 cents per share. The company reported quarterly sales of $1.140 billion which beat the analyst consensus estimate of $1.104 billion.
&#8220;In 2024, we implemented our largest US commercial sales force expansion, had two major product launches with Dexcom One+ and Stelo and submitted our G7 15-day product to the FDA,&#8221; said Kevin Sayer, Dexcom&#8217;s chairman, president and CEO. &#8220;As we enter 2025, we look forward to building on these investments as we unlock the next wave of access to Dexcom CGM globally.&#8221;
Dexcom reaffirmed its FY25 guidance for revenue of $4.60 billion (vs. cons. of $4.61 billion), adjusted gross profit margin of around 64%–65%, and adjusted operating margin of 21%. The company sees adjusted EBITDA margin of approximately 30%.
DexCom shares gained 0.3% to close at $84.09 on Thursday.
These analysts made changes to their price targets on DexCom following earnings announcement.
<ul>
<li>Morgan Stanley analyst Patrick Wood maintained DexCom with an Equal-Weight and raised the price target from $75 to $82.</li>
<li>Canaccord Genuity analyst William Plovanic maintained the stock with a Buy and raised the price target from $99 to $103.</li>
</ul>
Considering buying DXCM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14092114/image-140-1024x590.png" alt="" class="wp-image-783224" style="width:552px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14092114/image-140-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14092114/image-140-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14092114/image-140-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/14092114/image-140.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43692962/top-3-consumer-stocks-you-may-want-to-dump-in-february">Top 3 Consumer Stocks You May Want To Dump In February</a></li>
</ul>

DexCom Analysts Increase Their Forecasts After Q4 Earnings

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $99 to $103.

Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $103

Morgan Stanley analyst Patrick Wood maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Equal-Weight and raises the price target from $75 to $82.

Morgan Stanley Maintains Equal-Weight on DexCom, Raises Price Target to $82

Dexcom, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares are trading higher premarket on Friday after the company reported its&nbsp;fourth-quarter&nbsp;results&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43711731/dexcom-reports-fourth-quarter-and-fiscal-year-2024-financial-results" rel="noreferrer noopener">after Thursday&#8217;s closing bell</a>.&nbsp;
Revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion. U.S. revenue rose by 4%, while international revenue rose by 17% on a reported basis and 19% on an organic basis.
Adjusted gross profit declined to $661.2 million from $663.8 million in the same quarter a year ago, and the corresponding margin shrank to 59.4% from 64.2%.
Adjusted operating income declined to $209.5 million from $242.7 million a year ago quarter, with margin contracted 470 basis points Y/Y to 18.8%.
Adjusted EPS of 45 cents missed the analyst&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">consensus estimate of 50 cents</a>.&nbsp;
As of December 31, 2024, Dexcom had $2.58 billion in cash, cash equivalents&nbsp;and&nbsp;marketable securities, while its revolving credit facility remains undrawn.
Outlook: Dexcom reaffirmed its FY25 guidance for revenue of $4.60 billion (vs. cons. of $4.61 billion), adjusted gross profit margin of around 64%–65%, and<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> adjusted operating margin of 21%</a>.
The company sees adjusted EBITDA margin of approximately 30%.
Kevin Sayer, Dexcom&#8217;s chairman, president&nbsp;and&nbsp;CEO,&nbsp;said, &#8220;In 2024, we implemented our largest US commercial sales force expansion, had two major product launches with Dexcom One+ and Stelo and submitted our G7 15-day product to the FDA.&#8221;&nbsp;
&#8220;As we enter 2025, we look forward to building on these investments as we unlock the next wave of access to Dexcom CGM globally.&#8221;
Investors can gain exposure to the stock via&nbsp;First Trust Nasdaq Lux Digital Health Solutions ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKG#NASDAQ">EKG</a>) and&nbsp;Spinnaker ETF Series Langar Global HealthTech ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LGHT#NYSE">LGHT</a>).
Price Action: DexCom shares are up 2.87% at $86.50 premarket at the last check Friday.
Read Also:&nbsp;
<ul>
<li><a href="https://www.benzinga.com//node/43724889" target="_blank" rel="noreferrer noopener">If You Invested $100 In Bitcoin Last Valentine&#8217;s Day, Today It&#8217;d Be Worth More Than What An Average American Spends On Their Significant Other On The Day Of Love</a></li>
</ul>
Image via Shutterstock.

LGHT

Dexcom Q4 Earnings: Expanding Sales, New Products, Margin Pressure And More

DexCom shares are trading lower following a Q4 adjusted EPS miss.

Dexcom Sees FY25 Adj. EBITDA Margin 30%; Revenue Growth 14%; FY25 Revenue $4.60B.

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported quarterly earnings of $0.45 per share which missed the analyst consensus estimate of $0.50 by 10 percent. This is a 10 percent decrease over earnings of $0.50 per share from the same period last year. The company reported quarterly sales of $1.140 billion which beat the analyst consensus estimate of $1.104 billion by 3.22 percent. This is a 10.20 percent increase over sales of $1.034 billion the same period last year.

Earnings Beats

Earnings Misses

DexCom Q4 2024 Adj. EPS $0.45 Misses $0.50 Estimate, Sales $1.140B Beat $1.104B Estimate

Investors with significant funds have taken a bearish position in DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), a development that retail traders should be aware of.
This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in DXCM usually indicates foreknowledge of upcoming events.
Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 37% being bullish and 62% bearish. Of all the options we discovered, 7 are puts, valued at $421,287, and there was a single call, worth $49,500.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $87.5 for DexCom over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for DexCom's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of DexCom's whale activity within a strike price range from $80.0 to $87.5 in the last 30 days. 
<h3>DexCom Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739475030_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/14/25</td>
<td>$3.7</td>
<td>$3.5</td>
<td>$3.66</td>
<td>$84.00</td>
<td>$145.8K</td>
<td>83</td>
<td align="right">415</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/07/25</td>
<td>$5.3</td>
<td>$5.0</td>
<td>$5.1</td>
<td>$85.00</td>
<td>$86.6K</td>
<td>172</td>
<td align="right">0</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$15.4</td>
<td>$15.3</td>
<td>$15.4</td>
<td>$85.00</td>
<td>$53.9K</td>
<td>1.2K</td>
<td align="right">76</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$11.1</td>
<td>$10.9</td>
<td>$11.0</td>
<td>$80.00</td>
<td>$49.5K</td>
<td>1.4K</td>
<td align="right">74</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$80.00</td>
<td>$48.0K</td>
<td>1.5K</td>
<td align="right">169</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Present Market Standing of DexCom</h3>
<ul>
<li>Currently trading with a volume of 3,574,013, the DXCM's price is up by 0.13%, now at $83.98. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 0 days.</li>
</ul>
<h3>Expert Opinions on DexCom</h3>
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $109.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Baird upgraded its action to Outperform with a price target of $104. 
&#x2A; An analyst from Redburn Atlantic has elevated its stance to Buy, setting a new price target at $115. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for DexCom with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

DexCom Options Trading: A Deep Dive into Market Sentiment

ABNB

AENT

AGIO

ALNY

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BRKR

BTOC

CBRE

CEVA

CLBT

CNVS

COHU

CROX

CYBR

DDOG

DNOW

EEFT

EGAN

ELME

ELVA

FBRT

GDDY

GEHC

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LECO

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

Across the recent three months, 5 analysts have shared their insights on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $100.6, a high estimate of $115.00, and a low estimate of $91.00. Witnessing a positive shift, the current average has risen by 15.63% from the previous average price target of $87.00.
<img src="https://www.benzinga.com/files/images/story/2025/1738591230_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A clear picture of DexCom's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issie Kirby</td>
<td>Redburn Atlantic</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$89.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to DexCom. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of DexCom's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of DexCom's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>Get to Know DexCom Better</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>DexCom: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining DexCom's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.97% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: DexCom's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 13.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): DexCom's ROE stands out, surpassing industry averages. With an impressive ROE of 6.1%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): DexCom's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 2.05%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: DexCom's debt-to-equity ratio surpasses industry norms, standing at 1.31. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into DexCom Stock: Analyst Perspectives (5 Ratings)

Redburn Atlantic analyst Issie Kirby upgrades DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) from Neutral to Buy and raises the price target from $85 to $115.

Upgrades

Redburn Atlantic Upgrades DexCom to Buy, Raises Price Target to $115

Throughout the last three months, 11 analysts have evaluated DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $95.91, a high estimate of $115.00, and a low estimate of $85.00. This upward trend is evident, with the current average reflecting a 2.73% increase from the previous average price target of $93.36.
<img src="https://www.benzinga.com/files/images/story/2025/1737054064_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The perception of DexCom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$99.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of DexCom's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DexCom's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>All You Need to Know About DexCom</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Financial Insights: DexCom</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, DexCom showcased positive performance, achieving a revenue growth rate of 1.97% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: DexCom's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 13.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): DexCom's ROE excels beyond industry benchmarks, reaching 6.1%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 2.05%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.31, DexCom faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: DexCom Through The Eyes Of 11 Analysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>JP Morgan cut the price target for The Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) from $186 to $181. JP Morgan analyst Andrea Teixeira maintained an Overweight rating. Procter &amp; Gamble shares closed at $159.65 on Wednesday. <a href="https://www.benzinga.com/quote/PG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<ul>
<li>Canaccord Genuity slashed Concentrix Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NYSE">CNXC</a>) price target from $100 to $80. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. Concentrix shares closed at $47.47 on Wednesday. <a href="https://www.benzinga.com/quote/CNXC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JP Morgan cut the price target for The Hershey Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) from $171 to $151. JP Morgan analyst Ken Goldman maintained a Neutral rating. Hershey shares closed at $155.31 on Wednesday. <a href="https://www.benzinga.com/quote/HSY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities increased the price target for Cracker Barrel Old Country Store, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) from $48 to $51. Truist Securities analyst Jake Bartlett maintained a Hold rating. Cracker Barrel shares closed at $57.57 on Wednesday. <a href="https://www.benzinga.com/quote/CBRL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) price target from $86 to $104. Baird analyst Jeff Johnson upgraded the stock from Neutral to Outperform. DexCom shares settled at $80.40 on Wednesday. <a href="https://www.benzinga.com/quote/DXCM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank raised The Bank of New York Mellon Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) price target from $94 to $98. Deutsche Bank analyst Brian Bedell maintained a Buy rating. Bank of New York Mellon shares closed at $82.04 on Wednesday. <a href="https://www.benzinga.com/quote/BK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Citigroup slashed StoneCo Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STNE#NASDAQ">STNE</a>) price target from $19 to $9. Citigroup analyst Gustavo Schroden downgraded the stock from Buy to Neutral. StoneCo shares closed at $8.74 on Wednesday.  <a href="https://www.benzinga.com/quote/STNE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised the price target for Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) from $428 to $437. JP Morgan analyst Matthew Boss maintained an Overweight rating. Lululemon shares settled at $376.66 on Wednesday. <a href="https://www.benzinga.com/quote/LULU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Northland Capital Markets raised Vitesse Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTS#NYSE">VTS</a>) price target from $28 to $31. Northland Capital Markets analyst Bobby Brooks maintained an Outperform rating. Vitesse Energy shares closed at $27.12 on Wednesday. <a href="https://www.benzinga.com/quote/VTS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised The Goldman Sachs Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) price target from $550 to $605. JP Morgan analyst Kian Abouhossein maintained an Overweight rating. Goldman Sachs shares closed at $605.92 on Wednesday. <a href="https://www.benzinga.com/quote/GS/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43026927/how-to-earn-500-a-month-from-j-b-hunt-transport-stock-ahead-of-q4-earnings">How To Earn $500 A Month From J.B. Hunt Transport Stock Ahead Of Q4 Earnings</a></li>
</ul>

CBRL

CNXC

LULU

STNE

Lululemon To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Jeff Johnson upgraded the rating for DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) from Neutral to Outperform and raised the price target from $86 to $104. DexCom shares closed at $80.40 on Wednesday. <a href="https://www.benzinga.com/quote/DXCM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Steven Enders upgraded monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) from Neutral to Buy but lowered the price target from $302 to $298. Monday.Com shares closed at $234.15 on Wednesday. <a href="https://www.benzinga.com/quote/MNDY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst David Joyce upgraded the rating for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from Neutral to Buy and announced a $955 price target. Netflix shares closed at $848.26 on Wednesday. <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Joseph Spak upgraded Dana Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) from Neutral to Buy and raised the price target from $11 to $18. Dana shares closed at $12.07 on Wednesday. <a href="https://www.benzinga.com/quote/DAN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst Benjamin Nolan upgraded the rating for Canadian National Railway Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) from Hold to Buy but lowered the price target from $132 to $120. Canadian National Railway shares closed at $100.69 on Wednesday. <a href="https://www.benzinga.com/quote/CNI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NFLX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110-1024x578.png" alt="" class="wp-image-736905" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110-768x434.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/16091422/image-110.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43026927/how-to-earn-500-a-month-from-j-b-hunt-transport-stock-ahead-of-q4-earnings">How To Earn $500 A Month From J.B. Hunt Transport Stock Ahead Of Q4 Earnings</a></li>
</ul>

Pre-Market Outlook

MNDY

NFLX

This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

DexCom shares are trading higher after Baird upgraded the stock from Neutral to Outperform and raised its price target from $86 to $104.

Baird analyst Jeff Johnson upgrades DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) from Neutral to Outperform and raises the price target from $86 to $104.

Baird Upgrades DexCom to Outperform, Raises Price Target to $104

Press Releases

Dexcom Reports Third Quarter 2024 Financial Results

Dexcom Helps People With Diabetes Take the First Step to Discover What They're Made Of on World Diabetes Day

Dexcom and ŌURA Announce Strategic Partnership

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Dexcom Launches the First Generative AI Platform in Glucose Biosensing

DEXCOM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of DexCom, Inc. - DXCM

Dexcom to Present at 43rd Annual J.P. Morgan Healthcare Conference

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook

Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time.

Dexcom Reports Fourth Quarter and Fiscal Year 2024 Financial Results

GCTK

Abbott Laboratories

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Envista Holdings Corporation Common Stock

Envista Holdings

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Canaccord Genuity

Morgan Stanley

Redburn Atlantic

Baird

Citigroup

Screenshot 2024-12-03 at 7.43.04 PM

Biotech

Screenshot 2024-10-03 at 5.30.47 PM

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-08-23 at 5.43.44 PM

Poster Presentations, Upcoming Human Trials, Recently Secured Funding And More: Glucotrack&#39;s Plans To Transform The Continuous Glucose Monitoring Market

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Comments

DexCom

ニュース

パートナーシップ

ベンジンガ・グローバル